Latest Intelligence on Oncology in Europe

Published within

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

EASD 2009: Lantus defended amid allegations of increased cancer risk

Datamonitor attended this year's European Association for the Study of Diabetes meeting in Vienna, Austria. Following the issuance of guidance on a potential link between Lantus and increased cancer rates in June 2009, presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed.

Published By Datamonitor
14 Oct 2009
CommentWire
CommentWire

Eli Lilly: completes SGX acquisition

Eli Lilly has completed its purchase of US biotechnology company SGX Pharmaceuticals for $64m. The acquisition is expected to compliment Lilly's pursuit of innovative R&D programs, and represents a further investment by a leading pharmaceutical player in the promising US biotechnology industry.

Published By Datamonitor
21 Aug 2008
CommentWire
CommentWire

Eli Lilly: Gemzar gets Finnish approval

Regulatory officials in Finland have approved an expanded indication for Eli Lilly's [LLY] Gemzar (gemcitabine) in combination with paclitaxel for advanced breast cancer. Further EU and, most importantly, US approval should follow soon, providing Gemzar with a large range of indications and blockbuster status by the end of 2003.

Published By Datamonitor
02 Jul 2003
Expert View
Expert View

ESMO 2009: denosumab as potential new treatment option for skeletal-related events in cancer

Statistically significant positive results in two Phase III studies investigating denosumab in solid tumors and multiple myeloma have added to the ongoing excitement around Amgen's investigational product. These results, added to an impending decision from the FDA regarding approval, mean that a new treatment option for bone metastases in cancer patients could be on the market within months.

Published By Datamonitor
30 Sep 2009
Expert View
Expert View

ESMO 2009: findings confirm adjuvant use of aromatase inhibitors in early breast cancer

Positive data from the TEAM study, which is the largest of three trials investigating use of aromatase inhibitors in adjuvant breast cancer, confirmed what the oncology community already knows: adjuvant Aromasin is superior to tamoxifen in early-stage breast cancer. Despite these findings, however, Aromasin is unlikely to oust Arimidex as the leading aromatase inhibitor.

Published By Datamonitor
30 Sep 2009
Expert View
Expert View

ESMO 2009: new lease of life for Vectibix in colorectal cancer?

Results from two Phase III studies presented at the European Society for Medical Oncology Congress 2009 show statistically significant benefits via the addition of Vectibix to both first- and second-line chemotherapy for wild-type KRAS metastatic colorectal cancer. These positive data could help Vectibix to overcome Erbitux's first-to-market status and usurp its current position.

Published By Datamonitor
30 Sep 2009
Expert View
Expert View

ESMO 2009: novel 'super-selective' agent shows early signs of efficacy in metastatic melanoma

Phase I data for the orally available novel BRAF inhibitor PLX4032 presented at the European Society for Medical Oncology Congress 2009 are causing cautious excitement in the melanoma market. This step towards personalized cancer care has the potential to revolutionize treatment of this tumor type, but only if early efficacy signals are carried through to the end of late-phase clinical studies.

Published By Datamonitor
30 Sep 2009
Expert View
Expert View

ESMO 2010: Avastin's early success in metastatic ovarian cancer must be confirmed by mature data

At the 2010 European Society of Medical Oncology meeting, Avastin's dominance within the cancer market was strengthened by preliminary positive results from the ICON7 Phase III trial in newly diagnosed ovarian cancer. However, while these results may be enough for a regulatory submission, Avastin's chances of success would be improved greatly if backed up by overall survival data.

Published By Datamonitor
18 Nov 2010
CommentWire
CommentWire

ESMO 2010: cediranib fails pivotal trials leaving Avastin to dominate in colorectal cancer

During the 35th congress of the European Society of Medical Oncology in October, AstraZeneca revealed that its ambitious program to position cediranib as an agent of choice over Avastin in the treatment of first-line metastatic colorectal cancer has failed. Data presented from the Horizon II and Horizon III trials failed to show any meaningful clinical benefit over the control arm of either trial.

Published By Datamonitor
18 Nov 2010
CommentWire
CommentWire

ESMO 2010: GlaxoSmithKline's BRAF inhibitor shows promising early efficacy

In October 2010, Datamonitor attended the 35th congress of the European Society of Medical Oncology, during which results were presented showing that GSK2118436, GlaxoSmithKline's BRAF kinase inhibitor, reduced the overall size of brain metastasis in almost all patients. However, as this success has so far been proved only in early phase trials, GSK must prove this efficacy through mature data.

Published By Datamonitor
18 Nov 2010

« | ... | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | ... | » »|

No help is available.